Switch to:
Nivalis Therapeutics Inc (NAS:NVLS)
EV/EBITDA
0.19 (As of Today)

EV/EBITDA ratio is calculated as enterprise value divided by its EBITDA. As of today, Nivalis Therapeutics Inc's enterprise value is $-4.90 Mil. Nivalis Therapeutics Inc's earnings before depreciation and amortization for the trailing twelve months (TTM) ended in Mar. 2016 was $-26.39 Mil. Therefore, Nivalis Therapeutics Inc's EV/EBITDA ratio for today is 0.19.

NVLS' s EV/EBITDA Range Over the Past 10 Years
Min: 0   Max: 1.62
Current: 0.2

0
1.62

During the past 4 years, the highest EV/EBITDA Ratio of Nivalis Therapeutics Inc was 1.62. The lowest was 0.00. And the median was 0.00.

NVLS's EV/EBITDA is ranked higher than
95% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 21.11 vs. NVLS: 0.20 )

EV/EBITDA (Enterprise value/EBITDA) is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the P/E Ratio to determine the fair market value of a company.

As of today, Nivalis Therapeutics Inc's stock price is $4.87. Nivalis Therapeutics Inc's earnings per share for the trailing twelve months (TTM) ended in Mar. 2016 was $-2.73. Therefore, Nivalis Therapeutics Inc's P/E Ratio for today is .

The "classic" EV/EBITDA ratio is much better in capturing debt and net cash than the P/E Ratio.


Definition

Nivalis Therapeutics Inc's EV/EBITDA for today is calculated as:

EV/EBITDA=Enterprise Value (Today)/Earnings Before Depreciation and Amortization (TTM)
=-4.902/-26.386
=0.19

Nivalis Therapeutics Inc's current Enterprise Value is $-4.90 Mil.
Nivalis Therapeutics Inc's Earnings Before Depreciation and Amortization for the trailing twelve months (TTM) ended in Mar. 2016 was -5.837 (Jun. 2015 ) + -6.085 (Sep. 2015 ) + -6.611 (Dec. 2015 ) + -7.853 (Mar. 2016 ) = $-26.39 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.


Explanation

EV/EBITDA (Enterprise value/EBITDA) is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the P/E Ratio to determine the fair market value of a company.

Nivalis Therapeutics Inc's P/E Ratio for today is calculated as:

P/E Ratio=Share Price (Today)/Earnings Per Share (TTM)
=4.87/-2.733
=

Nivalis Therapeutics Inc's share price for today is $4.87.
Nivalis Therapeutics Inc's Earnings Per Share for the trailing twelve months (TTM) ended in Mar. 2016 was -1.41 (Jun. 2015 ) + -0.39 (Sep. 2015 ) + -0.423 (Dec. 2015 ) + -0.51 (Mar. 2016 ) = $-2.73.

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.

Study has found that the companies with the lowest EV/EBITDA outperforms companies measured as cheap by other ratios such as P/E Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Related Terms

Enterprise Value, Earnings Before Depreciation and Amortization, P/E Ratio


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.

Nivalis Therapeutics Inc Annual Data

Dec12Dec13Dec14Dec15
ev2ebitda 0.000.000.000.000.000.000.000.000.00-1.42

Nivalis Therapeutics Inc Quarterly Data

Dec13Mar14Jun14Sep14Dec14Mar15Jun15Sep15Dec15Mar16
ev2ebitda 0.000.000.000.000.000.00-6.35-5.49-1.420.60
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK